|
|
| | 1,2,5-Thiadiazolidin-3-one, 5-[(7R)-1-fluoro-5,6,7,8-tetrahydro-3-hydroxy-7-[(3-methylbutyl)amino]-2-naphthalenyl]-, 1,1-dioxide Basic information |
| Product Name: | 1,2,5-Thiadiazolidin-3-one, 5-[(7R)-1-fluoro-5,6,7,8-tetrahydro-3-hydroxy-7-[(3-methylbutyl)amino]-2-naphthalenyl]-, 1,1-dioxide | | Synonyms: | 1,2,5-Thiadiazolidin-3-one, 5-[(7R)-1-fluoro-5,6,7,8-tetrahydro-3-hydroxy-7-[(3-methylbutyl)amino]-2-naphthalenyl]-, 1,1-dioxide;ABBV-CLS-484;5-[(3R)-5-fluoro-7-hydroxy-3-(isopentylamino)tetralin-6-yl]-1,1-dioxo-1,2,5-thiadiazolidin-3-one;Osunprotafib;AC 484|||Osunprotafib|||AC484|||ABBV-CLS-484;(R)-5-(1-Fluoro-3-hydroxy-7-(isopentylamino)-5,6,7,8-tetrahydronaphthalen-2-yl)-1,2,5-thiadiazolidin-3-one 1,1-dioxide;A-484;Osunprotafib (ABBV-CLS-484) | | CAS: | 2489404-97-7 | | MF: | C17H24FN3O4S | | MW: | 385.45 | | EINECS: | | | Product Categories: | | | Mol File: | 2489404-97-7.mol | ![1,2,5-Thiadiazolidin-3-one, 5-[(7R)-1-fluoro-5,6,7,8-tetrahydro-3-hydroxy-7-[(3-methylbutyl)amino]-2-naphthalenyl]-, 1,1-dioxide Structure](CAS/20210305/GIF/2489404-97-7.gif) |
| | 1,2,5-Thiadiazolidin-3-one, 5-[(7R)-1-fluoro-5,6,7,8-tetrahydro-3-hydroxy-7-[(3-methylbutyl)amino]-2-naphthalenyl]-, 1,1-dioxide Chemical Properties |
| density | 1.41±0.1 g/cm3(Predicted) | | pka | 3.39±0.20(Predicted) | | form | Solid | | color | White to light yellow |
| | 1,2,5-Thiadiazolidin-3-one, 5-[(7R)-1-fluoro-5,6,7,8-tetrahydro-3-hydroxy-7-[(3-methylbutyl)amino]-2-naphthalenyl]-, 1,1-dioxide Usage And Synthesis |
| Uses | Osunprotafib (ABBV-CLS-484) is a potent PTPN1 and PTPN2 inhibitor with subnanomolar activity. Osunprotafib has antitumor activity, enhances the immune response and increases the sensitivity of tumors to immune-mediated killing[1]. | | in vivo | Osunprotafib promotes anti-tumor immunity as a monotherapy and, when combined with anti-PD-1, leads to significant tumor regression, even in models resistant to anti-PD-1 treatment, such as 4T1 and EMT6[3].
| | References | [1] Philip R. Kym, et al. Protein tyrosine phosphatase inhibitors and methods of use thereof. WO2022056281A1.
[2] Arvin Iracheta-Vellve, et al. Targeting the immune checkpoint PTPN2 with ABBV-CLS-484 inflames the tumor microenvironment and unleashes potent CD8+ T cell immunity. Cancer Res (2022) 82 (12_Supplement): 606.
[3] Christina K, et al. ABBV-CLS-484: An active site PTPN2/N1 inhibitor that augments the immune response and sensitizes tumors to immune-mediated killing. Cancer Res (2022) 82 (12_Supplement): ND06. |
| | 1,2,5-Thiadiazolidin-3-one, 5-[(7R)-1-fluoro-5,6,7,8-tetrahydro-3-hydroxy-7-[(3-methylbutyl)amino]-2-naphthalenyl]-, 1,1-dioxide Preparation Products And Raw materials |
|